Sunshine Biopharma Files 8-K on Financials
Ticker: SBFMW · Form: 8-K · Filed: May 22, 2024 · CIK: 1402328
| Field | Detail |
|---|---|
| Company | Sunshine Biopharma, Inc (SBFMW) |
| Form Type | 8-K |
| Filed Date | May 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, sec-filing
Related Tickers: SBFM
TL;DR
Sunshine Biopharma filed an 8-K on financials, check for updates.
AI Summary
Sunshine Biopharma, Inc. filed an 8-K on May 22, 2024, reporting on events as of May 21, 2024. The filing pertains to the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or material events were detailed in the provided text excerpt.
Why It Matters
This 8-K filing indicates that Sunshine Biopharma is providing updates on its financial condition and operations to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing header and does not contain specific material events or financial data that would indicate a high-risk situation.
Key Players & Entities
- Sunshine Biopharma, Inc. (company) — Registrant
- May 21, 2024 (date) — Earliest event reported
- May 22, 2024 (date) — Date of report
- 1177 Avenue of the Americas (location) — Company business address
FAQ
What specific financial information is being reported in this 8-K?
The provided excerpt of the 8-K filing does not detail specific financial information, only that the report pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
What is the exact date of the earliest event reported in this filing?
The earliest event reported is as of May 21, 2024.
What is Sunshine Biopharma, Inc.'s state of incorporation?
Sunshine Biopharma, Inc. is incorporated in Colorado.
What is the company's IRS Employer ID Number?
The IRS Employer ID No. for Sunshine Biopharma, Inc. is 20-5566275.
What is the company's business address?
The company's business address is 1177 Avenue of the Americas, 5th Floor, New York, NY 10036.
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-05-22 16:11:07
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC
Filing Documents
- sunshine_8k.htm (8-K) — 27KB
- sunshine_ex9901.htm (EX-99.1) — 13KB
- image_001.jpg (GRAPHIC) — 6KB
- 0001683168-24-003777.txt ( ) — 265KB
- sbfm-20240521.xsd (EX-101.SCH) — 3KB
- sbfm-20240521_def.xml (EX-101.DEF) — 26KB
- sbfm-20240521_lab.xml (EX-101.LAB) — 36KB
- sbfm-20240521_pre.xml (EX-101.PRE) — 25KB
- sunshine_8k_htm.xml (XML) — 5KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On May 21, 2024, Sunshine Biopharma, Inc. (the "Company") issued a press release announcing the Company's financial results for the period ended March 31, 2024. The press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release 104 Cover Page Interactive Data File (formatted in Inline XBRL). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 22, 2024 SUNSHINE BIOPHARMA, INC. By: /s/ Dr. Steve N. Slilaty Dr. Steve N. Slilaty, Chief Executive Officer 3